Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
PYXS
Pyxis Oncology, Inc.
MICVO is an antibody-drug conjugate (ADC), the core modality Pyxis is developing.
|
$92.41M |
$1.35
-9.40%
|
|
FBIO
Fortress Biotech, Inc.
Fortress Biotech directly encompasses oncology-focused biotech through its portfolio (e.g., Mustang Bio) and related assets, aligning with Biotech - Oncology.
|
$92.24M |
$3.12
+0.81%
|
|
CBUS
Cibus, Inc.
Reported contract research revenue indicates direct R&D services provided to clients alongside platform licensing.
|
$91.66M |
$1.68
+5.66%
|
|
ADVM
Adverum Biotechnologies, Inc.
Lead program Ixo-vec is a gene therapy for an ocular indication, placing Adverum in the Biotech - Gene Therapy category.
|
$91.49M |
$4.38
+0.34%
|
|
SLSN
Solesence, Inc. Common Stock
Solésence operates as a contract development and manufacturing organization (CDMO) for beauty products, matching Contract Manufacturing Organizations.
|
$90.22M |
$1.24
-3.13%
|
|
COYA
Coya Therapeutics, Inc.
COYA's autologous regulatory T cell therapy program (COYA 101) represents a direct cell therapy product line.
|
$89.65M |
$5.36
-0.09%
|
|
CALC
CalciMedica, Inc.
CalciMedica's lead candidate Auxora is a CRAC channel inhibitor, i.e., an ion channel modulator.
|
$88.72M |
$5.77
+17.76%
|
|
INO
Inovio Pharmaceuticals, Inc.
INO's core DNA medicines platform and lead candidate INO-3107 are gene therapy products based on DNA plasmids delivered via CELLECTRA; maps to gene therapy.
|
$84.50M |
$1.57
-0.94%
|
|
CRDL
Cardiol Therapeutics Inc.
Cardiol Therapeutics' lead drug is a cardiovascular therapy targeting heart disease.
|
$84.33M |
$1.01
-0.98%
|
|
TIL
Instil Bio, Inc.
Instil Bio's lead candidate AXN-2510/IMM2510 is a bispecific antibody, placing the company squarely in the Bispecific Antibodies investable theme.
|
$82.97M |
$5.79
-52.89%
|
|
CSBR
Champions Oncology, Inc.
Company provides outsourced drug development and preclinical/clinical research services to biopharma (CRO-style).
|
$82.73M |
$5.78
-3.75%
|
|
BMEA
Biomea Fusion, Inc.
Direct product category: Biomea Fusion is developing oral small molecule therapeutics, including icovamenib and BMF-650.
|
$82.72M |
$1.36
-1.80%
|
|
CAMP
CAMP4 Therapeutics Corporation
Direct product category: oligonucleotide therapeutics (RNA Actuating Platform) using ASOs to upregulate gene expression.
|
$82.26M |
$4.59
+12.62%
|
|
ANVS
Annovis Bio, Inc.
The lead candidate Buntanetap is positioned as an Alzheimer's disease (AD) therapeutics program with cognition endpoints and an FDA-aligned path toward NDA filings.
|
$80.48M |
$4.17
+10.16%
|
|
MCRB
Seres Therapeutics, Inc.
SER-155 is a cultivated live biotherapeutic product (cell therapy) comprising a defined bacterial consortium.
|
$79.93M |
$9.49
+3.94%
|
|
ATOS
Atossa Therapeutics, Inc.
Atossa is a clinical-stage biotech focused on oncology with Z-endoxifen as its lead cancer therapy candidate.
|
$79.72M |
$0.66
+7.68%
|
|
ACRV
Acrivon Therapeutics, Inc. Common Stock
Companion Diagnostics: The company develops the OncoSignature companion diagnostic to identify patients likely to respond to its therapies.
|
$79.58M |
$2.56
+1.19%
|
|
VOR
Vor Biopharma Inc.
Vor Biopharma is focused on engineered cell therapies (eHSCs) and trem-cel, a cell therapy product.
|
$79.24M |
$12.50
+3.05%
|
|
PLRX
Pliant Therapeutics, Inc.
Company's lead and mid-stage assets include oral small-molecule therapeutics (bexotegrast and PLN-101095) targeting integrin pathways.
|
$79.19M |
$1.29
+0.39%
|
|
XGN
Exagen Inc.
Exagen's biomarker-based tests (e.g., AVISE CTD, SLE T-cell markers, RA33) align with companion diagnostics.
|
$78.99M |
$3.24
-9.75%
|
|
CGTX
Cognition Therapeutics, Inc.
CT1812 (zervimesine) is an orally delivered small-molecule therapeutic, the core product of the company.
|
$77.88M |
$1.03
-2.36%
|
|
ASRT
Assertio Holdings, Inc.
ROLVEDON and related oncology-supportive care products position Assertio in Biotech - Oncology as its growth drivers.
|
$77.44M |
$11.99
-0.66%
|
|
IGMS
IGM Biosciences, Inc.
IGMS's engineered antibodies are monoclonal antibody therapeutics, a core product category.
|
$76.35M |
$1.27
|
|
EQ
Equillium, Inc.
Equillium's pipeline focuses on immunology/inflammatory diseases, aligning with Immunology Therapeutics.
|
$76.16M |
$1.20
-6.64%
|
|
RFL
Rafael Holdings, Inc.
NPC1 rare-disease program (Trappsol Cyclo) places Rafael Holdings in the Biotech - Rare Diseases category.
|
$75.07M |
$1.45
|
|
BHST
BioHarvest Sciences Inc. Common Stock
BioHarvest operates a CDMO division providing contract development and manufacturing services for plant-based compounds.
|
$74.71M |
$4.20
-2.55%
|
|
VANI
Vivani Medical, Inc.
Vivani's NanoPortal is a proprietary drug-implant platform enabling ultra long-acting, localized drug delivery.
|
$74.65M |
$1.30
+3.17%
|
|
CLNN
Clene Inc.
Clene's proprietary clean-surfaced nanotechnology platform operates as a drug delivery platform for CNM-Au8.
|
$72.13M |
$7.22
|
|
CMPX
Compass Therapeutics, Inc.
Compass Therapeutics is an oncology-focused biotech developing cancer therapies, anchoring its business in oncology.
|
$71.84M |
$5.53
-2.90%
|
|
XBIT
XBiotech Inc.
Core products are monoclonal antibody therapeutics derived from the True Human platform.
|
$71.65M |
$2.31
-1.70%
|
|
MNOV
MediciNova, Inc.
MN-166 (ibudilast) and MN-001 (tipelukast) are oral small-molecule therapeutics in MediciNova's development pipeline.
|
$70.63M |
$1.30
-9.38%
|
|
IMUX
Immunic, Inc.
Immunic's lead programs are oral, small-molecule therapeutics (e.g., vidofludimus calcium and IMU-856).
|
$68.07M |
$0.69
+0.07%
|
Showing page 17 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
